Avacta updates on MHRA status after fake email circulates

AIM-listed Avacta Group provide an update to the market today on the MHRA status of SARS-CoV-2 Antigen Lateral Flow Test by its partner Mologic Limited.

The response from Avacta titled ‘response to speculation’ appeared to be provided due to a fake email that was fabricated by a private investor under the guise of the MHRA and doing the rounds across share chatter yesterday.

In the statement, Avacta reaffirmed that neither Avacta nor Mologic have had any update so far and as usual will confirm to the market when it has something to officially say on the matter:

To date, neither Avacta nor Mologic have received any update from the MHRA. Avacta will update the market when it is in a position to do so.

Avacta – Response to speculation

The share price of Avacta tumbled slightly in the immediate aftermath of the announcement, but has since recovered to match yesterday’s closing price.

Let's Talk

Buying Tremor SharesYou should have trusted your instinct- easy to say now I suppose. … Read More
Omega very bullishBullish? Looks sheepish now! Read More
Surely Amigo won't go bustErr looks like the the judge man doesn't care, Amigo better p … Read More
Argo shares back to the moooooon? …I actually like that its main listing is in London, less competiti … Read More
What shares do you think could go …SNG after today's news. If they can get this out anytime soon … Read More
Hey, profit awaits! Free Sharebuyers Newsletter

Receive hot tips you can profit from - only sent when it matters. Twitter: @ShareBuyers.